Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Overweight or Obesity and Elevated Liver Fat: early-phase trial registry

1 of 1 indexed Overweight or Obesity and Elevated Liver Fat trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Overweight or Obesity and Elevated Liver Fat: 1 US clinical trial tracked, 1 recruiting.

Overweight or Obesity and Elevated Liver Fat is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Amgen, running 1 of these trials.

Enrollment posture brief

Registry condition overweight-or-obesity-and-elevated-liver-fat

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Overweight or Obesity an (this)Overweight or Obesity an (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Overweight or Obesity and Elevated Liver Fat

Overweight or Obesity and Elevated Liver Fat lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Overweight or Obesity and Elevated Liver Fat on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Overweight or Obesity and Elevated Liver Fat is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Amgen 1 trials

Named interventions

Most-linked intervention names on Overweight or Obesity and Elevated Liver Fat records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Maridebart cafraglutide Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Overweight or Obesity and Elevated Liver Fat trials. A trial with sites in several states counts in each.

Texas 1 trials
Nevada 1 trials
Maryland 1 trials
Florida 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Overweight or Obesity and Elevated Liver Fat page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Overweight or Obesity and Elevated Liver Fat trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Amgen sponsors the most Overweight or Obesity and Elevated Liver Fat trials on record, review their full trial history before evaluating a specific study. See Amgen's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Overweight or Obesity and Elevated Liver Fat condition card totals 1 registered trials; most-linked intervention Maridebart cafraglutide; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.